FDA holds public hearing on plan for genetically modified salmon
The Food and Drug Administration held a public hearing on Monday on a request to market and sell genetically modified salmon in the U.S.

A Massachusetts company called AquaBounty takes eggs from Atlantic salmon and inserts a growth hormone gene from a Chinook salmon and another gene from the ocean pout, an eel-like species. The fish are raised in Panama and can grow to large sizes in 18 months instead of three years.

Critics said the company hasn't provided enough information about the health and environmental impacts of the modified fish. The FDA commissioner will make the final decision on the matter.

Get the Story:
Fears over modified salmon voiced (The Washington Post 9/21)
Panel Leans in Favor of Engineered Salmon (The New York Times 9/21)